RxDoctor Payments Data

Michael Gallentine, MD

Urology · Evansville, INNPI 1356311583

Payments from drug & device makers

$1,233in general payments, 2019–2025

Across 25 payments — averaging $49.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$194
  • EDAP Technomed Inc$192
  • C. R. Bard, Inc. & Subsidiaries$174
  • Medtronic$161
  • Laborie Medical Technologies Corp.$149
  • AbbVie$93
  • plus $270 from 4 others

What the payments were for

  • Food & beverage$1,233100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,233 in reported general payments places this provider in the 25th percentile of 272 urology providers in Indiana.

See all urology providers in Indiana

Medicare billing

Part B allowed, 2024
$246,879
Medicare patients
532
Services billed
6,397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron101$84,896
MyrbetriqMirabegron102$72,141
XyostedTestosterone Enanthate13$7,955
Estradiol82$4,939
Potassium Citrate ErPotassium Citrate44$3,496
Tamsulosin Hcl296$3,175
Trimethoprim29$1,746
Testosterone Cypionate75$1,652
NitrofurantoinNitrofurantoin Macrocrystal34$1,470
Testosterone11$721
Cephalexin62$551
Finasteride54$542
Oxybutynin Chloride ErOxybutynin Chloride23$468
Cefdinir26$419
Allopurinol23$337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$56$72,141102 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 272 urology providers in Indiana.

Other urology in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →